Ceptaris Therapeutics, Inc. Seeking FDA Approval of Drug
3/1/2013 8:25:10 AM
More...
|
Ceptaris Therapeutics, Inc. Announces Publication in JAMA Dermatology of Positive Clinical Results for Mechlorethamine Gel in Early Stage Mycosis Fungoides, the Most Common Type of Cutaneous T-Cell Lymphoma
1/30/2013 9:50:27 AM
More...
|
Ceptaris Therapeutics, Inc. Secures $10 Million in Series D-1 Financing
6/5/2012 7:36:17 AM
More...
|
Ceptaris Therapeutics, Inc. Secures $15 Million in Venture Debt Financing
2/21/2012 7:28:38 AM
More...
|
Ceptaris Therapeutics, Inc. Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel
1/18/2012 6:52:10 AM
More...
|
Yaupon Therapeutics Inc. Changes Name to Ceptaris Therapeutics, Inc.
1/5/2012 7:12:14 AM
More...
|
FDA Accepts Filing of New Drug Application (NDA) for Yaupon Therapeutics Inc.'s Proprietary Gel Formulation of Mechlorethamine Hydrochloride
10/4/2011 8:46:14 AM
More...
|
Yaupon Therapeutics Inc. Secures $14.4 Million in Series D Financing
8/11/2011 7:19:35 AM
More...
|
Yaupon Therapeutics Inc. Submits New Drug Application for Proprietary Gel Formulation of Mechlorethamine Hydrochloride
7/28/2011 7:09:27 AM
More...
|
Yaupon Therapeutics Inc. Appoints New Management Team
7/18/2011 9:43:34 AM
More...
|
|